-
Chardan Downgrades Regeneron Pharmaceuticals, Notes Valuation Concerns
Monday, August 31, 2015 - 1:31pm | 362Read More...Gbola Amusa, Chardan Capital Markets' head of healthcare research, commented in a note on Monday that investors should be "more selective" in the biotech space. As such, the analyst downgraded shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to Neutral from Buy with an unchanged $565 price...
-
FDA Panel Clears Product Path For Sanofi, Regeneron Pharmaceuticals
Wednesday, June 10, 2015 - 10:52am | 316Read More...A key regulatory advisory panel recommended approval of a cholesterol treatment under joint development by Sanofi SA (ADR) (NYSE: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN), the companies said Wednesday. A final ruling is expected July 24 from the Food and Drug Administration,...
-
Regeneron Earnings: Small Growth Expected, Driven By Eylea
Wednesday, May 6, 2015 - 5:30pm | 385Read More...Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is scheduled to announce its first quarter financial results on Thursday, and both the crowd and experts expect to see some growth, although the Street is slightly more bullish. According to Estimize, Wall Street analysts model consensus earnings of...
-
UPDATE: Barclays Initiates Coverage On Regeneron
Tuesday, January 6, 2015 - 12:28pm | 200Read More...Geoffrey Meacham of Barclays initiated coverage of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) on Tuesday with an Equal-Weight rating and $450 price target as approval and modest growth profile of key drugs are already expected by investors. Based on Meacham's survey of 50 U.S....
